Zobrazeno 1 - 10
of 52
pro vyhledávání: '"Kerstin Kapp"'
Autor:
Kerstin Kapp, Barbara Volz, Michael A. Curran, Detlef Oswald, Burghardt Wittig, Manuel Schmidt
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-15 (2019)
Abstract Background Toll-like receptor 9 agonists are potent activators of the immune system. Their clinical potential in immunotherapy against metastatic cancers is being evaluated across a number of clinical trials. TLR9 agonists are DNA-based mole
Externí odkaz:
https://doaj.org/article/101097251a4e4531acc519a5dcf5ca5a
Autor:
Kerstin Kapp, Barbara Volz, Detlef Oswald, Burghardt Wittig, Matthias Baumann, Manuel Schmidt
Publikováno v:
OncoImmunology, Vol 8, Iss 12 (2019)
Activation of Toll-like receptor 9 (TLR9) is known to foster innate and adaptive immune responses and thus improve immune-mediated control of malignant disease. Lefitolimod is a potent TLR9 agonist without chemical modification developed for immunoth
Externí odkaz:
https://doaj.org/article/c96f530412b04c249834ec0be09d1935
Autor:
Barbara Volz, Manuel Schmidt, Kerstin Heinrich, Kerstin Kapp, Matthias Schroff, Burghardt Wittig
Publikováno v:
Molecular Therapy: Oncolytics, Vol 3, Iss C (2016)
The tumor vaccine MGN1601 was designed and developed for treatment of metastatic renal cell carcinoma (mRCC). MGN1601 consists of a combination of fourfold gene-modified cells with the toll-like receptor 9 agonist dSLIM, a powerful connector of innat
Externí odkaz:
https://doaj.org/article/d6d316b31c4c4525a5697f6c8061be34
Publikováno v:
Molecular Therapy: Nucleic Acids, Vol 3, Iss C (2014)
Toll-like receptors are sensing modulators of the innate immune system. One member of this protein family, Toll-like receptor (TLR)-9, is increasingly being investigated as therapeutic target for infectious diseases and cancer. Double-Stem Loop Immun
Externí odkaz:
https://doaj.org/article/cd362b38f0e243bcafc875010750b3bb
Autor:
Anne Endmann, Katharina Klünder, Kerstin Kapp, Oliver Riede, Detlef Oswald, Eduard G Talman, Matthias Schroff, Christiane Kleuss, Marcel H J Ruiters, Christiane Juhls
Publikováno v:
PLoS ONE, Vol 9, Iss 7, p e101715 (2014)
Currently marketed vaccines against hepatitis B virus (HBV) based on the small (S) hepatitis B surface antigen (HBsAg) fail to induce a protective immune response in about 10% of vaccinees. DNA vaccination and the inclusion of PreS1 and PreS2 domains
Externí odkaz:
https://doaj.org/article/236f808e02ba4a9888d1cf0f72287c2d
Autor:
Wagner Antonio Paz, Soraya de Paula Paim, Gustavo Lanza de Mello, Kerstin Kapp Rangel, Rodrigo Campos Christo, Robson Gonçalves, Maria Eulália Silva, Adelanir Antônio Barroso, Antônio Francisco de Souza
Publikováno v:
Revista Brasileira de Cancerologia, Vol 47, Iss 3 (2001)
A dissecção axilar representa hoje um dos tópicos mais controversos no tratamento do câncer de mama inicial. Paralelamente à necessidade do estadiamento axilar acurado está a elevada morbidade associada à linfadenectomia convencional. A bióps
Externí odkaz:
https://doaj.org/article/d621503ec5364244a0b28506140389e1
Autor:
Kerstin Kapp Rangel, Paulo Guilherme de Oliveira Salles, Ana Luiza de Freitas Magalhães Gomes, Wagner Antonio Paz, Marina Paixão de Madrid Whyte
Publikováno v:
Mastology. 30
Introduction: Triple-negative breast cancer (TNBC) does not express estrogen and progesterone receptors, and does not overexpress the human epidermal growth factor 2. It represents 15%‒20% of breast cancers and have worse prognosis, with scarce ava
Autor:
Detlef Oswald, Burghardt Wittig, Manuel Schmidt, Matthias Baumann, Barbara Volz, Kerstin Kapp
Publikováno v:
OncoImmunology, Vol 8, Iss 12 (2019)
Oncoimmunology
Oncoimmunology
Activation of Toll-like receptor 9 (TLR9) is known to foster innate and adaptive immune responses and thus improve immune-mediated control of malignant disease. Lefitolimod is a potent TLR9 agonist without chemical modification developed for immunoth
Autor:
Anne Deuretzbacher, Elke Baumeister, Andreas Beilhack, Markus Kapp, Harald Wajant, Carolin Köchel, Nergui Dagvadorj, Daniela Weisenberger, Isabell Lang, Johannes Trebing, Kerstin Kapp, Thomas Hünig, Hermann Einsele, Götz Ulrich Grigoleit
Publikováno v:
Cancer Immunology, Immunotherapy. 66:319-332
Due to its immunogenicity and overexpression concomitant with leukemia progression, Wilms tumor protein 1 (WT1) is of particular interest for immunotherapy of AML relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT). So far, W
Autor:
Lisa Schneider, Jacqueline Schneider, Nadine Gollinge, Stefanie Jänsch, Burghardt Wittig, Kerstin Kapp, Christiane Kleuss, Matthias Schroff
Publikováno v:
Immunity, Inflammation and Disease
Introduction DNA‐based TLR9 agonists are potent activators of the immune system. ProMune® and dSLIM® belong to different families of TLR9 agonists and both have been established as cancer immunotherapeutics in clinical proof‐of‐concept studie